NovoFocusTM CRC 2.0 Test is a next generation sequencing (NGS)-based assay that analyzes 50 genes related to Colorectal Cancer (CRC) for clinically important alterations at the DNA level and some other genes for Microsatellite Instability (MSI) status. These genes are known to be relevant for the diagnosis and/or treatment of various CRC according to National Comprehensive Cancer Network (NCCN) guideline and the medical literature.
|NovoFocus™ NSCLC 2.0|
|Cancer Type||Colorectal Cancer|
|Sample Type||FFPE Blood/Plasma (Extracted DNA)|
|Turnaround Time||14 Calendar Days|
Novogene Quality Assurance
NovoFocus™ CRC 2.0 interrogates the complete coding region of 50 genes and introns of 10 genes. It can detect genomic abnormalities (SNV, InDel, CNV and Fusion) and MSI and provide targeted therapy/immunotherapy options. Besides, it analyzes pharmacogenomics and provides chemotherapy options.
Comprehensive analytical validation has been completed ant the test includes rigorous quality control measures.
With leading-edge sequencing solutions and superior process efficiency, Novogene offers highly competitive prices for all our service.
Who Benefit from NovoFocus™ CRC 2.0?
NovoFocus™ CRC 2.0 is suitable for all CRC patients, especially for the following:
- Patients newly diagnosed with Colorectal Cancer (CRC)
- CRC patients with drug resistance to multiple types of chemotherapy
- CRC patients planning to use targeted therapy
- CRC patients who are treated with chemotherapies and would like to know the efficacy and toxicity of these drugs
What Clinical Information Does NovoFocus™ CRC 2.0 Provide?
Provide the information about relevant biomarkers and genomic alterations to help match patients to targeted therapies.
Provide the SNP information related to efficacy and toxicity of chemotherapies.
|50 genes on targeted therapy|
|9 genes on chemotherapy|